Dean L. Kellogg Jr.
A geriatrician who co-leads clinical trials of rapamycin in older adults at the Barshop Institute, with a focus on safety and cardiovascular effects.
Professor of Medicine, UT Health San Antonio · Barshop Institute for Longevity and Aging Studies · GRECC, South Texas Veterans Health Care System
Portrait: UT Health San Antonio
Dean Kellogg is a physician-scientist with both an MD and a PhD. He is a professor in the Division of Geriatrics, Gerontology and Palliative Medicine at UT Health San Antonio, and he works at the Barshop Institute for Longevity and Aging Studies. His lab studies how drugs that may slow aging affect people, paying particular attention to drug safety and to the blood vessels and heart.
In the 2018 pilot trial in this Atlas, he was the senior author. Twenty-five healthy people aged 70 to 95 took either 1 mg of rapamycin or a placebo each day, and 11 on rapamycin and 14 on placebo completed at least 8 weeks. The question was simple: is it safe? There were small drops in some red blood cell measures, but blood sugar, insulin sensitivity, thinking tests and walking tests did not change over that short time.
Kellogg now co-leads a larger National Institute on Aging-funded program at UT Health San Antonio. It looks for the lowest rapamycin dose that reaches useful biological targets in older adults and includes a randomized, placebo-controlled trial of about 84 people.
Milestones in the Atlas
A selection, not a full bibliography: only papers that meet the Atlas inclusion criteria.
| Year | Evidence | Study |
|---|---|---|
| 2018 | H | A randomized control trial to establish the feasibility and safety of rapamycin treatment in an older human cohort: Immunological, physical performance, and cognitive effects. KRA2018 Senior author of a small randomized pilot (25 adults aged 70-95) showing that 8+ weeks of daily low-dose rapamycin was well tolerated, with no change in blood glucose or insulin sensitivity. |
Co-authors in the Atlas 5
People with a profile here who share at least one study with Dean L. Kellogg Jr..
ShowHide
- Adriana D. Benavides Immunologist who worked at UT Health San Antonio and the Children's Hospital of Philadelphia, and a co-author of the first small safety trial of rapamycin in healthy older people
- Ellen Kraig Immunologist at UT Health San Antonio who studies how aging changes immune regulation and who led the first small safety trial of rapamycin in healthy older people at the Barshop Institute
- Martin A. Javors Pharmacologist and professor at UT Health San Antonio who directs an analytical laboratory for biochemical and drug measurements, and a co-author of rapamycin studies in mice and in older people
- Nicolas Musi Endocrinologist and aging researcher who directs the Division of Endocrinology, Diabetes and Metabolism and the Diabetes and Aging Center at Cedars-Sinai, and who studies how aging drives insulin resistance, frailty and senescence
- Qianqian Liu Biostatistician on one of the first randomised pilot trials of rapamycin's safety in older adults
Every researcher with a profile →
Thank you. That helps us know which pages have been read by someone who knows the work.
Thank you. We will check it and correct the page.
Thank you. Your answer was counted anonymously.